Table 6. Comparison of clinical malaria with any parasitaemia during the rainy season following the IPTc intervention between infants and older children.

Age group	Treatment group	Events	PWAR1	Rate*	Protective Efficacy (95% CI)	p-value
15–23 months (Formerly 3–11 moths)	Placebo	6	1629	0.37
	SP bimonthly	16	2156	0.74	−50% (−34%, 84%)	0.070
	AS+AQ bimonthly	13	2108	0.62	−40% (−68%, 81%)	0.152
	AS+AQ monthly	21	2152	0.98	−62% (−3%, 88%)	0.014
24–71 months (Formerly 12–59 months)	Placebo	40	10038	0.40
	SP bimonthly	43	8428	0.51	−22% (−23%, 51%)	0.131
	AS+AQ bimonthly	28	7470	0.37	6% (−56%, 44%)	0.405
	AS+AQ monthly	39	9076	0.43	−7% (−48%, 42%)	0.369

PWAR¹- person weeks at risk; ^*Per 100 child years at risk; Protective efficacy calculated on the basis of incidence rates (1−IRR)×100.